Skip To Main Content
Maaisha Osman on Muck Rack

Maaisha Osman

Verified
Washington, D.C.
As seen in: Citeline, The Boston Globe, STAT, NewsBreak, Online News Association, BioSpace, Spectrum, Generics Bulletin, Scrip, The Pink Sheet, Bay State Banner and
health policy reporter @PharmaPinkSheet • previously @InHealthPolicy • cinephile signal: maaisha.07 Send tips to maaisha.osman@citeline.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Maaisha

Contact Maaisha, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

US Officials Want to Counter China’s Pharma Rise, But Pricing Policies May Be Doing The Opposite

|
By Maaisha Osman Verified
| The Pink Sheet Verified
If the prescription drug market splits into a US system supplied domestically and a rest-of-world market supplied by China at a lower cost, global investors likely will want exposure to both sides. Washington's anti-China push may have a blind spot. (Shutterstock) Key Takeaways President Trump's push to raise drug prices abroad carries an unintended risk that as Western drugmakers pull back from European launches, Chinese companies will fill the gap.
Open in Who Shared Issue with article?

RP-1 Trial May Offer Blueprint For Intratumoral Immunotherapy Development

|
By Maaisha Osman Verified
| The Pink Sheet Verified
Replimune's RP-1 trial could set the standard for the design and measure of future intratumoral immunotherapy studies after a US FDA advisory committee meeting that included many questions about the efficacy data. Advisory committee members said the RP-1 review exposed a decade-long gap in intratumoral immunotherapy trial standards.
Open in Who Shared Issue with article?

US FDA Panel Admits Trial Data Messy, Still Backs Replimune Melanoma Treatment RP-1

|
By Maaisha Osman Verified
| The Pink Sheet Verified
The absence of a better treatment option, a durable response plateau suggesting a systemic effect and complete responses in non-injected lesions not expected from retreatment alone moved committee members to support RP1. The FDA goal for a decision on Replimune’s experimental melanoma treatment is Aug. 2.
Open in Who Shared Issue with article?
See all 959 licensed articles (967 Total)